MEI Pharma, Inc.
MEIP
$2.04
$0.042.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | -- |
| Cost of Revenue | 61.00K | 1.86M | 3.78M | 5.03M | 3.68M |
| Gross Profit | -61.00K | -1.86M | -3.78M | -5.03M | -3.68M |
| SG&A Expenses | 2.24M | 3.39M | 3.99M | 4.61M | 7.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.25M | 5.25M | 7.86M | 9.83M | 11.63M |
| Operating Income | -2.25M | -5.25M | -7.86M | -9.83M | -11.63M |
| Income Before Tax | -2.68M | -8.01M | -18.41M | -9.13M | -11.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.68M | -8.01M | -18.41M | -9.13M | -11.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.68M | -8.01M | -18.41M | -9.13M | -11.06M |
| EBIT | -2.25M | -5.25M | -7.86M | -9.83M | -11.63M |
| EBITDA | -2.25M | -4.88M | -7.74M | -9.74M | -11.55M |
| EPS Basic | -0.40 | -1.20 | -2.76 | -1.37 | -1.66 |
| Normalized Basic EPS | -0.14 | -0.46 | -0.68 | -0.86 | -1.01 |
| EPS Diluted | -0.40 | -1.20 | -2.76 | -1.37 | -1.66 |
| Normalized Diluted EPS | -0.14 | -0.46 | -0.68 | -0.86 | -1.01 |
| Average Basic Shares Outstanding | 6.66M | 6.66M | 6.66M | 6.66M | 6.66M |
| Average Diluted Shares Outstanding | 6.66M | 6.66M | 6.66M | 6.66M | 6.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |